Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Commentary|Podcasts|June 10, 2026
Previewing Key Myeloma Presentations to Watch at EHA 2026: With Joshua Richter, MD
Author(s)Joshua Richter, MD
Fact checked by: Chris Ryan, Ashling Wahner
Joshua Richter, MD, previews some of the most anticipated multiple myeloma presentations ahead of the 2026 EHA Congress.
Advertisement
Advertisement
Welcome to OncLive On Air®! I'm your host today, Chris Ryan
Related to this article
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
Experts shared the key data that stood out in GU oncology at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement